IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Abroad (travel likely)RecruitingPHASE2

Conditions

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia (PCL)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First Hospital of Jilin University, Changchun, Jilin, China
Contact: Study coordinator (FengYan Jin, MD, PhD) · fengyanjin@jlu.edu.cn · +8617843082307

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

B-Cell Lymphoma · Myelodysplastic Syndromes (MDS) · Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Houston, United States

A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia

Abroad (travel likely)RecruitingPHASE1

Shanghai, China

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Duarte, United States

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Ames, United States · Ames, United States